Glasgow-based life sciences scaleup EnteroBiotix has secured £19m to support its clinical trials of microbiome drugs used to treat irritable bowel syndrome (IBS). IBS affects up to one in ten people, with up to twice as many women diagnosed compared to men. The investment will fund the firm’s clinical trial
Kirstie Pickering
Glasgow-based life sciences scaleup EnteroBiotix has secured £19m to support its clinical trials of microbiome drugs used to treat irritable bowel syndrome (IBS).
IBS affects up to one in ten people, with up to twice as many women diagnosed compared to men.
The investment will fund the firm’s clinical trial for its EBX-102-02 IBS drug, which will involve around 300 patients. Top line efficacy data from the clinical trial is expected during the second half of 2027.
The latest round was led by life science investor Thairm Bio and the Scottish National Investment Bank, with participation from existing investors too. EnteroBiotix has now raised over £65m of total investment since the company was founded in 2017.
“Our clinical data indicates that EBX-102-02 has the potential to deliver transformative outcomes for patients with IBS,” says Dr James McIlroy, CEO and founder of EnteroBiotix.
“Our mission is to redefine the standard of care in gastrointestinal disease, improving the lives of patients with IBS while building a leading global biopharmaceutical company from our base in Scotland.”
EnteroBiotix partakes in a number of strategic partnerships and research collaborations, including with Imperial College London. Its clinical pipeline spans IBS, liver cirrhosis and blood cancer.
